We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol.
- Authors
Home, P D; Pocock, S J; Beck-Nielsen, H; Gomis, R; Hanefeld, M; Dargie, H; Komajda, M; Gubb, J; Biswas, N; Jones, N P
- Abstract
Studies suggest that in addition to blood glucose concentrations, thiazolidinediones such as rosiglitazone improve some cardiovascular (CV) risk factors and surrogate markers, that are abnormal in type 2 diabetes. However, fluid retention might lead to cardiac failure in a minority of people. The aim of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study is to evaluate the long-term impact of these effects on CV outcomes, as well as on long-term glycaemic control, in people with type 2 diabetes.
- Publication
Diabetologia, 2005, Vol 48, Issue 9, p1726
- ISSN
0012-186X
- Publication type
Journal Article
- DOI
10.1007/s00125-005-1869-1